NTI 2.90% 6.7¢ neurotech international limited

Ann: Clarification Statement, page-5

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,908 Posts.
    lightbulb Created with Sketch. 390
    Best case scenario in my view (and limited knowledge of medical journals)...

    1) Finish writing the paper. It would have been pretty much written already. The hypothesis, null hypothesis, methodology, and analysis will have been written early on. They will have to perform the analysis, plug in the results, and write the conclusion. Rough guess on my part... three weeks (late January).

    2) Submit the paper for publication.

    3) Complete the peer review. Here's where the "interim results" release will pay a dividend; there's probably a dozen peers out there all foaming at the mouth for the chance to see the final results! Rough guess on my part... three weeks (mid February).

    4) Paper is accepted for publication, subject to editorial review, at some point in the future, when space is available.

    5) Top line results announced in a letter in the next issue of the journal (March? issue), and also provided to Neurotech to support their FDA application.
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
(20min delay)
Last
6.7¢
Change
-0.002(2.90%)
Mkt cap ! $64.55M
Open High Low Value Volume
6.9¢ 6.9¢ 6.7¢ $7.631K 113.2K

Buyers (Bids)

No. Vol. Price($)
4 577217 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
6.7¢ 70967 2
View Market Depth
Last trade - 10.29am 25/11/2024 (20 minute delay) ?
NTI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.